STCube Inc Cash Flow Conversion Efficiency

Latest as of June 2026: -0.065x

STCube Inc cash flow conversion efficiency. Based on the latest financial reports, STCube Inc (052020) has a cash flow conversion efficiency ratio of -0.065x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.92 Billion ≈ $-2.65 Million USD) by net assets (₩60.29 Billion ≈ $40.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of STCube Inc (2009–2025)

Cash flow conversion efficiency of STCube Inc from 2009 to 2025. This chart illustrates how STCube Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest STCube Inc stock price today for real-time trading data and today's change.

STCube Inc Cash Flow Conversion Ratio Explained

STCube Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

STCube Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of STCube Inc ranked by their cash flow conversion efficiency. Also see 052020 stock market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Kangstem Biotech Co. Ltd
KQ:217730
-0.087x
Bellevue Group AG
SW:BBN
0.150x
Norsk Titanium AS
OL:NTI
-0.732x
UVAT Technology Co Ltd
TWO:3580
0.047x
PT Mandiri Herindo Adiperkasa Tbk
JK:MAHA
-0.050x
Vardhman Holdings Limited
NSE:VHL
0.000x
Excel Industries Limited
NSE:EXCELINDUS
0.010x
Aroa Biosurgery Ltd
AU:ARX
0.045x

Annual Cash Flow Conversion Efficiency for STCube Inc (2009–2025)

The table below shows the annual cash flow conversion efficiency of STCube Inc from 2009 to 2025. Review cash generation quality of STCube Inc to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩72.12 Billion
≈ $48.88 Million
₩-19.78 Billion
≈ $-13.40 Million
-0.274x -10.84%
2024-12-31 ₩94.28 Billion
≈ $63.89 Million
₩-23.32 Billion
≈ $-15.80 Million
-0.247x +64.51%
2023-12-31 ₩35.31 Billion
≈ $23.93 Million
₩-24.61 Billion
≈ $-16.68 Million
-0.697x -121.89%
2022-12-31 ₩51.22 Billion
≈ $34.71 Million
₩-16.09 Billion
≈ $-10.90 Million
-0.314x +70.39%
2021-12-31 ₩16.16 Billion
≈ $10.95 Million
₩-17.15 Billion
≈ $-11.62 Million
-1.061x -271.33%
2020-12-31 ₩36.03 Billion
≈ $24.41 Million
₩-10.29 Billion
≈ $-6.97 Million
-0.286x -4165.71%
2019-12-31 ₩28.82 Billion
≈ $19.53 Million
₩-192.99 Million
≈ $-130.79K
-0.007x +95.65%
2018-12-31 ₩38.70 Billion
≈ $26.23 Million
₩-5.96 Billion
≈ $-4.04 Million
-0.154x +74.13%
2017-12-31 ₩19.12 Billion
≈ $12.96 Million
₩-11.38 Billion
≈ $-7.71 Million
-0.595x -386.91%
2016-12-31 ₩29.24 Billion
≈ $19.81 Million
₩6.07 Billion
≈ $4.11 Million
0.207x +203.54%
2015-12-31 ₩20.91 Billion
≈ $14.17 Million
₩-4.19 Billion
≈ $-2.84 Million
-0.200x -182.38%
2012-12-31 ₩8.79 Billion
≈ $5.96 Million
₩2.14 Billion
≈ $1.45 Million
0.243x +203.88%
2011-12-31 ₩9.97 Billion
≈ $6.76 Million
₩-2.33 Billion
≈ $-1.58 Million
-0.234x -74.55%
2010-12-31 ₩11.74 Billion
≈ $7.95 Million
₩-1.57 Billion
≈ $-1.07 Million
-0.134x -244.26%
2009-12-31 ₩16.63 Billion
≈ $11.27 Million
₩1.55 Billion
≈ $1.05 Million
0.093x --

About STCube Inc

KQ:052020 Korea Electronic Equipment & Parts
Market Cap
$119.13 Million
₩175.78 Billion KRW
Market Cap Rank
#18343 Global
#810 in Korea
Share Price
₩6570.00
Change (1 day)
+3.14%
52-Week Range
₩6370.00 - ₩22100.00
All Time High
₩24627.95
About

STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a tech… Read more